Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 3/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.53 |
| ▸ | BCHE | P06276 | 3/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34474746 | 1.00 | CCR5 (0.53) | CCR5OPRM1BCHEHSD11B1ACHE | |
| SCHEMBL12347237 | 0.92 | OPRM1 (0.51) | CCR5OPRM1BCHEHSD11B1ACHE | |
| SCHEMBL8567376 | 0.90 | CCR5 (0.52) | CCR5OPRM1BCHEHSD11B1ACHE | |
| SCHEMBL8578092 | 0.89 | HSD11B1 (0.48) | CCR5OPRM1BCHEHSD11B1ACHE | |
| SCHEMBL34473195 | 0.89 | HSD11B1 (0.48) | CCR5OPRM1BCHEHSD11B1ACHE | |
| SCHEMBL8574081 | 0.89 | HSD11B1 (0.51) | CCR5OPRM1BCHEHSD11B1SIGMAR1 | |
| SCHEMBL34473196 | 0.89 | HSD11B1 (0.48) | CCR5OPRM1BCHEHSD11B1ACHE | |
| SCHEMBL31210944 | 0.88 | HSD11B1 (0.48) | CCR5OPRM1BCHEHSD11B1ACHE | |
| SCHEMBL12355143 | 0.87 | HSD11B1 (0.47) | CCR5OPRM1BCHEHSD11B1ACHE | |
| SCHEMBL7507555 | 0.87 | SIGMAR1 (0.51) | OPRM1BCHEACHESIGMAR1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| EP-0723545-B1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LAB (US) | 2002-05-08 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5580872-A | ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| WO-1995010519-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | CCR5 4158/4885OPRM1 3693/4885BCHE 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.